A Phase II, Pharmacokinetic and Biologic Correlative Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Renal Cell Carcinoma (RCC).
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2015
At a glance
- Drugs Vorinostat (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 29 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2010 Primary endpoint 'Objective clinical response rate' has not been met.
- 05 Mar 2010 Results presented at ASCO Genitourinary Cancers Symposium 2010.